HAYATI Launches Disposable Shisha Vape in the UK with Dual MTL and DTL Modes

Nov.25.2024
HAYATI Launches Disposable Shisha Vape in the UK with Dual MTL and DTL Modes
The HAYATI brand has introduced its new Hayati Shisha 15000 disposable vape to the UK market. The product, supporting both MTL and DTL vaping modes, is listed on multiple UK-focused online vape retail websites.

Disclaimer

 

  • This article is intended solely for internal industry communication and does not constitute an endorsement of any brand or product.
  • The images presented in this article are for factual illustration purposes only and should not be interpreted as advertisements for any product.
  • Access to this article is prohibited for minors.

 

2Firsts has observed that several vape brands have recently launched their own disposable shisha-style vape products. Vape brand HAYATI also introduced the Hayati Shisha 15000 to the UK market, now available on local vape distributor websites.

 

Key Features of the Hayati Shisha 15000:

 

HAYATI Launches Disposable Shisha Vape in the UK with Dual MTL and DTL Modes
Hayati Shisha 15000 Specifications | Image source: 2Firsts

 

Hayati Shisha 15000 stands out with its choice of two nicotine levels: 50 mg (5%) or nicotine-free, and it supports both MTL (mouth-to-lung) and DTL (direct-to-lung) vaping modes.

 

HAYATI Launches Disposable Shisha Vape in the UK with Dual MTL and DTL Modes
Hayati Shisha 15000|Image source: vapesourcing

 

In terms of design, like recent disposable shisha-style vape products from brands such as HQD, OXBAR, and Kangvape, the Hayati Shisha 15000 adopts a cylindrical shape, aligning with current market trends for disposable shisha vapes.

 

The Hayati Shisha 15000 has already appeared on UK vape retailer websites like vapesourcing.uk, ideavape, and ninja-vapes with a status marked as "COMING SOON." However, it has not yet been featured on the official HAYATI brand website.

 

HAYATI Launches Disposable Shisha Vape in the UK with Dual MTL and DTL Modes
Hayati Shisha 15000 Product Page | Image source: vapesourcing

 

Notably, the Hayati Shisha 15000 is not listed in the UK Medicines and Healthcare Products Regulatory Agency (MHRA) vaping products database.

 

HAYATI Launches Disposable Shisha Vape in the UK with Dual MTL and DTL Modes
UK Medicines and Healthcare products Regulatory Agency vaping products search system | Image source: MHRA

 

According to the HAYATI official website, the brand belongs to PAX Innovations (Shenzhen) Limited, which submits all product registration applications to the MHRA. The website also mentions "PAX Manufacturing" and provides a relevant link.

 

HAYATI Launches Disposable Shisha Vape in the UK with Dual MTL and DTL Modes
PAX official website | Image source: PAX

 

PAX's official website states that the company was established in Hong Kong in 2021. Its founder, Mr. He, is a veteran expert in the vape industry with a long history of research and innovation in e-cigarette products.

 

2Firsts will continue to track trends and developments in the disposable shisha-style vape product market, ensuring the public receives accurate and authoritative industry updates.

 


 

2Firsts' product column remains committed to delivering readers the latest product updates in the new tobacco field. We invite readers to submit insights and news on e-cigarette developments.

 

For unique perspectives or information, please get in touch with us at info@2firsts.com.

 

JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
Product | KT&G Launches lil HYBRID 3.0 Misty Rosé Edition II in South Korea With Two Pink Finishes at 88,000 Won
Product | KT&G Launches lil HYBRID 3.0 Misty Rosé Edition II in South Korea With Two Pink Finishes at 88,000 Won
South Korean tobacco company KT&G launched the limited-edition lil HYBRID 3.0 Misty Rosé Edition II on September 30, 2026, following the original Misty Rosé Edition introduced in November 2025. The new release comes in two pink finishes, Bloom Rosé and Viva Rosé, each priced at 88,000 won. Both versions initially went on sale through the lil Store online shop and lil MINIMALIUM flagship stores. From October 7, Bloom Rosé became available at approximately 1,500 lil Station retail outlets nationwide. The release retains the existing lil HYBRID 3.0 hybrid heated tobacco platform, with changes focused on exterior design and distribution.
product
Oct.10
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
The Philippines’ Bureau of Internal Revenue is intensifying enforcement against illicit vape and tobacco products ahead of the Christmas shopping season, directing regional and enforcement offices to strengthen monitoring of production sites, warehouses, distribution channels and retail outlets. The BIR destroyed 240,550 illicit vape products in August with an estimated tax liability of about PHP1.53 billion. A nationwide tax-compliance operation in July also inspected 3,590 businesses involved in tobacco and vapor products.
Regulations
Sep.17 by 2Firsts Perspectives
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
South Korea Fully Reviews Nicotine-Analog and Nicotine-Free Vape Liquid Imports, With Over 99% From China and Chinese Supply-Chain Documents Under Scrutiny
South Korea Fully Reviews Nicotine-Analog and Nicotine-Free Vape Liquid Imports, With Over 99% From China and Chinese Supply-Chain Documents Under Scrutiny
Korea Customs Service has tightened import controls on nicotine-analog and nicotine-free e-cigarette liquids, placing the products under 100% document review and subjecting all e-cigarette liquid import declarations to pre-clearance ingredient analysis. As of September 20, 2026, South Korea had imported about 15 metric tons of nicotine-analog liquids, 99.99% from China, and about 316 metric tons of nicotine-free liquids, including roughly 315 metric tons, or 99.7%, from China. The measures follow South Korea's April expansion of its tobacco definition to include synthetic nicotine products and include new checks on Chinese manufacturing, transaction and export documentation.
Sep.24
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22